<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278069</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-PETAML-043</org_study_id>
    <nct_id>NCT01278069</nct_id>
  </id_info>
  <brief_title>PET-CT in AML for Detection of Extramedullary AML Manifestations</brief_title>
  <acronym>PETAML</acronym>
  <official_title>PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myeloid Sarcoma (or granulocytic Sarcoma or Chloroma) is well defined by the WHO. However,
      there are currently no data about the prevalence, sites of occurence and thr prognostic value
      for patients with AML with this finding. Information about this condition is based on
      retrospective analyses since there have been no studies trying to define the role of myeloid
      sarcoma in AML so far. This observational trial will include adult patients with newly
      diagnosed and relapsed AML in order to perform 18FDG-PET-CT imaging prior to induction
      chemotherapy. Furthermore, a second 18FDG-PET-CT will be performed after induction
      chemotherapy to define the responsiveness of these tumors to chemotherapy. The primary
      endpoint of this study is the prevalence of 18FDG-PET-CT positive extramedullary AML
      manifestations (myeloid sarcoma) in patients with newly diagnosed or relapsed AML.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">93</enrollment>
  <condition>Newly Diagnosed or Relapsed Acute Myeloid Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients or Outpatients with newly diagnosed or relapsed AML AML
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed or relapsed AML

          -  AML FAB M0-2, M4-7

          -  Signed informed consent after patient information

          -  Male and female patients with AML age 18-80

          -  18FDG-PET-CT is available within a period of 5 days after diagnosis of AML

        Exclusion Criteria:

          -  AML FAB M3 (Promyelocytic Leukemia)

          -  lacking willingness to cooperate

          -  pregnancy or insufficient contraception

          -  18FDG-PET-CT is not available within a period of 5 days after diagnosis of AML

          -  Medical condition of the patients requires an immediated start of chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Saxony</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Friedrich Stölzel, M.D.</investigator_full_name>
    <investigator_title>PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations</investigator_title>
  </responsible_party>
  <keyword>Acute myeloid Leukemia</keyword>
  <keyword>Myeloid Sarcoma</keyword>
  <keyword>Extramedullary Acute myeloid Leukemia</keyword>
  <keyword>18FDG-PET-CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

